Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas

CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988

Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research